Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PGT 121

Next Previous
Search
Drug Profile

PGT 121

Alternative Names: PGT121; PGT121.414.LS; PGT121LS

Latest Information Update: 13 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theraclone Sciences
  • Developer Centre for the AIDS Programme of Research in South Africa; International AIDS Vaccine Initiative; The Ragon Institute of MGH, MIT and Harvard
  • Class Antiretrovirals; Antivirals; Monoclonal antibodies
  • Mechanism of Action HIV envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 01 Feb 2025 National Institute of Allergy and Infectious Diseases plans a phase II trial in HIV infections (Prevention, Combination therapy) USA, Brazil, Peru, South Africa (IV, Infusion), in February 2025 (NCT06812494)
  • 24 Jul 2024 National Institute of Allergy and Infectious Diseases (NIAID) plans a phase I safety and PK trial for HIV-1 infections (In neonates, In volunteers, Monotherapy, combination therapy) in USA, Brazil, Kenya, Puerto Rico and South Africa (SC, Injection) in November 2024 (NCT06517693)
  • 18 Jul 2024 National Institute of Allergy and Infectious Diseases (NIAID) plans a phase I/II trial for HIV infections (combination therapy, Treatment experienced, In adults, In adolescent, In childrens) in Botswana (IV, infusion) in September 2024 (NCT06508749)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top